H2020Staff exchange2015–2019

SCAFFY · Bio-scaffold engineered device for brown adipose tissue regeneration

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2015-10-01 → 2019-09-30
EU contribution
€864,000
Participants
6
Scheme
MSCA-RISE

Lines connect the coordinator with its partners.

Results in brief

Bio-scaffold engineered device for brown adipose tissue regeneration

Obesity and cardio-metabolic disease represent major health problems with vast impacts on the European healthcare systems. Recent advances in tissue engineering and regenerative medicine can be used to design novel techniques aiming to boost human metabolism; thus being promising candidates for human metabolic disease treatment. However, the development of these techniques requires the creation of new technology and knowledge in chemistry, biomaterials, toxicology, physiology, molecular biology as well as business management and marketing. SMEs do not have the technical capabilities or the facilities to conduct R&D activities at the level of excellence required for such development. Academic institutions have the capacity and facilities to conduct research and design activities necessary to develop the concept into a market product. However, they do not have a viable supply chain to develop the prototype post project and to exploit the product in the market. To solve this intersectoral problem, the SCAFFY project will create an effective intersectoral co-operation between academia institutions and SMEs to advance the concept of bio-scaffold for brown adipose tissue (BAT) regeneration. The regeneration of BAT has been largely ignored in tissue engineering thus far. This is because relevant R&D attempts were led by either the public or the private sector alone but never by a joint-venture of the two. As a result, academic organizations have faced challenges in finding the right application for the consumer market, while SMEs have been struggling to find the resources to conduct the necessary state of the art research. Therfore, the main objectives of the SCAFFY consortium are: putting together knowledge, research expertise and resources from two large academic participants with business, market and commercialization experience from three SMEs to: i) ensure a high degree of collaboration between academic and industrial participants though Networking Activities, ii) go beyond the current state of the art though Researcher & Training Activities, iii) increase intersectoral transfer of knowledge though Workshop Activities, iv) ensure high level of innovation capacity though Innovation Activities, v) ensure communication to the scientific community and to the public though Dissemination and Outreach Activities.

Data: CORDIS, © European Union

Project objective

Obesity and cardio-metabolic disease represent major health problems with vast impacts on the European healthcare systems. Recent advances in tissue engineering and regenerative medicine can be used to design novel techniques aiming to boost human metabolism; thus being promising candidates for human metabolic disease treatment. However, the development of these techniques requires the creation of new technology and knowledge in chemistry, biomaterials, toxicology, physiology, molecular biology as well as business management and marketing. SMEs do not have the technical capabilities or the facilities to conduct R&D activities at the level of excellence required for such development. Academic institutions have the capacity and facilities to conduct research and design activities necessary to develop the concept into a market product. However, they do not have a viable supply chain to develop the prototype post project and to exploit the product in the market. To solve this intersectoral problem, the SCAFFY project will create an effective intersectoral co-operation between academia institutions and SMEs to advance the concept of bio-scaffold for brown adipose tissue regeneration. SCAFFY will put together knowledge, research expertise and resources from two large academic participants with business, market and commercialization experience from three SMEs to: i) ensure a high degree of collaboration between academic and industrial participants though Networking Activities, ii) go beyond the current state of the art though Researcher & Training Activities, iii) increase intersectoral transfer of knowledge though Workshop Activities, iv) ensure high level of innovation capacity though Innovation Activities, v) ensure communication to the scientific community and to the public though Dissemination and Outreach Activities.

Original text from CORDIS.

Participants

  • VRIJE UNIVERSITEIT BRUSSEL · Bruxelles / BrusselCoordinatorBelgium
  • CHRISTOS PAPADOPOULOS & SIA OE · KARDITSAGreece
  • HISTOCELL SL · Derio BizkaiaSpain
  • IMEDICA SA · BUCARESTIRomania
  • TECHNICAL PROTEINS NANOBIOTECHNOLOGY SL · VALLADOLIDSpain
  • UNIVERSITA DEGLI STUDI DI BRESCIA · BresciaItaly

Links

Data: CORDIS, © European Union